Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a cash flow conversion efficiency ratio of 0.000x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-172.75K) by net assets ($495.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Drugs Made In America Acquisition II Cor market capitalisation for the company's overall valuation and market capitalisation.
Drugs Made In America Acquisition II Corp. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition II Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Drugs Made In America Acquisition II Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition II Corp. Ordinary Shares ranked by their cash flow conversion efficiency. Explore how high is Drugs Made In America Acquisition II Cor's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
-0.003x |
|
First Watch Restaurant Group Inc
NASDAQ:FWRG
|
0.043x |
|
Sobute New Materials Co Ltd
SHG:603916
|
0.044x |
|
Catapult Group International Ltd
AU:CAT
|
0.334x |
|
Algoma Central Corporation
TO:ALC
|
0.043x |
|
Citycon Oyj
HE:CTY1S
|
0.006x |
|
PNE AG
XETRA:PNE3
|
-0.170x |
|
Sincere Navigation Corp
TW:2605
|
0.034x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025. View Drugs Made In America Acquisition II Cor share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $487.16 Million | $-1.02 Million | -0.002x | -100.13% |
| 2024-12-31 | $-116.72K | $-194.30K | 1.665x | -- |
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp… Read more